Claims for Patent: 8,653,085
✉ Email this page to a colleague
Summary for Patent: 8,653,085
Title: | Diketopiperazine salts for drug delivery and related methods |
Abstract: | Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization. |
Inventor(s): | Leone-Bay; Andrea (Ridgefield, CT), Moye-Sherman; Destardi (Newburgh, NY), Wilson; Bryan R. (Bedford, NY) |
Assignee: | Mankind Corporation (Valencia, CA) |
Application Number: | 13/592,142 |
Patent Claims: | 1. A microparticulate system for drug delivery comprising a composition comprising: microparticles of a pharmaceutically acceptable anion of a heterocyclic compound and a
biologically active agent, wherein said microparticles release a biologically active agent; and a cation; wherein said anion is 3,6-di(citraconate-4-aminobutyl)-2,5-diketopiperazine, 3,6-di(oxalate-4-aminobutyl)-2,5-diketopiperazine,
3,6-di(malonate-4-aminobutyl)-2,5-diketopiperazine, 3,6-di(succinate-4-aminobutyl)-2,5-diketopiperazine, 3,6-di(maleate-4-aminobutyl)-2,5-diketopiperazine, 3,6-di(fumarate-4-aminobutyl)-2,5-diketopiperazine or
3,6-di(glutarate-4-aminobutyl)-2,5-diketopiperazine.
2. The microparticulate system of claim 1 wherein said biologically active agent is a hormone, an anticoagulant, an immunomodulating agent, a cytotoxic agent, an antibiotic, an antiviral, an antisense, an antigen, an antibody or an active fragment or an analog thereof. 3. The microparticulate system of claim 1 wherein said biologically active agent is insulin, a cannabinoid, a heparin, calcitonin, felbamate, parathyroid hormone or a fragment thereof, growth hormone, erythropoietin, glucagon-like peptide-1, somatotrophin-releasing hormone, follicle stimulating hormone, cromolyn, adiponectin, RNAse, ghrelin, zidovudine, didanosine, tetrahydrocannabinol, atropine, granulocyte colony stimulating factor, lamotrigine, chorionic gonadotropin releasing factor, luteinizing releasing hormone, beta-galactosidase or Argatroban. 4. The microparticulate system of claim 1 wherein said cation is sodium, potassium, calcium, lithium, triethylamine, butylamine, diethanolamine or triethanolamine. 5. The microparticulate system of claim 1 wherein the anion is 3,6-di(fumarate-4-aminobutyl)-2,5-diketopiperazine. 6. The microparticulate system of claim 1 wherein said microparticles have a diameter between about 0.5 microns and about ten microns. 7. The microparticulate system of claim 1 wherein said composition comprises a suspension for drug delivery. 8. The microparticulate system of claim 7, wherein said suspension is administered orally. 9. The microparticulate system of claim 1, wherein said biologically active agent is glucagon-like peptide-1. 10. The microparticulate system of claim 9, wherein said cation is sodium, potassium, calcium, lithium, triethylamine, butylamine, diethanolamine, or triethanolamine. 11. The microparticulate system of claim 9 wherein the anion is 3,6-di(fumarate-4-aminobutyl)-2,5-diketopiperazine. 12. The microparticulate system of claim 1, wherein said microparticles have a diameter between about 0.5 microns and about ten microns. 13. The microparticulate system of claim 11, wherein said composition comprises a suspension for drug delivery. 14. The microparticulate system of claim 13, wherein said suspension is administered orally. 15. A dry powder composition comprising the microparticles of claim 1. 16. A dry powder composition comprising the microparticles of claim 9. |
Details for Patent 8,653,085
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Ferring Pharmaceuticals Inc. | NOVAREL | chorionic gonadotropin | For Injection | 017016 | 01/15/1974 | ⤷ Try a Trial | 2024-08-23 |
Ferring Pharmaceuticals Inc. | NOVAREL | chorionic gonadotropin | For Injection | 017016 | 12/27/1984 | ⤷ Try a Trial | 2024-08-23 |
Ferring Pharmaceuticals Inc. | NOVAREL | chorionic gonadotropin | For Injection | 017016 | 02/15/1985 | ⤷ Try a Trial | 2024-08-23 |
Ferring Pharmaceuticals Inc. | NOVAREL | chorionic gonadotropin | For Injection | 017016 | 02/16/1990 | ⤷ Try a Trial | 2024-08-23 |
Bel-mar Laboratories, Inc. | CHORIONIC GONADOTROPIN | chorionic gonadotropin | Injection | 017054 | 03/26/1974 | ⤷ Try a Trial | 2024-08-23 |
Fresenius Kabi Usa, Llc | CHORIONIC GONADOTROPIN | chorionic gonadotropin | For Injection | 017067 | 03/05/1973 | ⤷ Try a Trial | 2024-08-23 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.